Educated Mononuclear Cell Product for Autoimmune T Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like type 1 diabetes are inadequate due to their inability to comprehensively modulate the immune system, leading to persistent autoimmunity and beta-cell destruction.
Innovation Solution
A method involving the use of a bioreactor device to co-culture mononuclear cells from patients with umbilical cord blood stem cells, modulating the T cell compartment to reduce autoreactivity and enhance beta-cell function, thereby improving insulin production and glycemic control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for autoimmune diseases, then treatment simplicity is maintained, but the ability to modulate the immune system comprehensively is insufficient, leading to persistent autoimmunity
Solution Approach 1:
The treatment process is segmented into distinct phases: (1) isolation of mononuclear cells from patient blood, (2) co-culture with umbilical cord blood stem cells in a bioreactor, (3) education/modulation of T cells, and (4) reinfusion of educated cells. This segmentation allows each step to be optimized independently while achieving comprehensive immune modulation.
Solution Approach 2:
Umbilical cord blood stem cells serve as an intermediary mediator that educates and modulates autoreactive T cells. The stem cells interact with patient mononuclear cells in a controlled bioreactor environment, transforming harmful autoreactive T cells into non-autoreactive cells without directly attacking the autoimmune pathology.
2Object-affected harmful factors
If the bioreactor co-culture method is used to educate mononuclear cells, then autoreactivity in T cells is reduced, but the treatment process becomes more complex and time-consuming
Solution Approach 1:
The bioreactor is pre-prepared with a conditioned environment containing umbilical cord blood stem cells before patient cell introduction. This preliminary setup ensures that when patient mononuclear cells are added, the educational/modulating environment is already optimized, reducing overall treatment time while maintaining effectiveness.
Solution Approach 2:
The bioreactor system allows precise control of co-culture parameters including cell ratios, nutrient composition, oxygen levels, and interaction time. By optimizing these parameters, the treatment achieves effective T cell education in reduced timeframes compared to conventional prolonged immunosuppressive therapies.
3Object-generated harmful factors
If current immunosuppressive therapies are applied, then immune response is suppressed, but beta-cell function is not enhanced and insulin production remains inadequate
Solution Approach 1:
The treatment converts harmful autoreactive T cells into beneficial non-autoreactive cells through the bioreactor co-culture process. Instead of merely suppressing the immune response, the umbilical cord blood stem cells actively reprogram the T cells, transforming the harmful autoimmune mechanism into a protective, non-autoreactive state that supports beta-cell survival and function.
Solution Approach 2:
The therapy combines multiple therapeutic elements: patient's own mononuclear cells, umbilical cord blood stem cells, controlled bioreactor environment, and optimized co-culture conditions. This composite approach simultaneously achieves immune modulation and beta-cell support, addressing both the harmful autoimmune attack and the need for enhanced insulin production.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The described invention provides a pharmaceutical composition comprising a therapeutic amount of an educated mononuclear cell product, a process for preparing the educated mononuclear cell product, and a method for treating a disease characterized by lymphocyte autoreactivity. Mononuclear cells from a diseased subject are co-cultured with a viable population of adherent umbilical cord blood stem cells at at least 80% confluence to form an educated mononuclear cell product. A therapeutic amount of the educated mononuclear cell product is returned by infusion intravascularly to the subject. The therapeutic amount is effective to modulate autoreactivity in a T cell compartment of the subject and to reduce symptoms of the disease characterized by lymphocyte autoreactivity.